Novel Lipids
AssigneeSignpath Pharma, Inc.
InventorsJames McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine, Daniel Emil Levy
Life of this patent
Estimating the term…
Abstract
The present invention includes compound having the following structural formula:
Claims34
A compound of Formula I,
- wherein,
- R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R3 is
- R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
- R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R8 is H or a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- X is a direct linkage, CH2, O or NH;
- Y is a direct linkage, CH2, O or NH;
- and,
- Each stereogenic center is independently R, S or racemic.
A method of preparing a compound of Formula I
- wherein,
- R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R3 is
- R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
- R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R8 is H or a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- X is a direct linkage, CH2, O or NH;
- Y is a direct linkage, CH2, O or NH;
- and,
- Each stereogenic center is independently R, S or racemic;
- Comprising the steps of:
- (1) Converting the hydroxyl groups of a compound of Formula II to esters, carbonates, carbamates, or collectively to an acetal or a ketal
- wherein, all substitutions are defined as above;
- and
- (2) Converting a phosphorus-bound OH group to O—R4, wherein R4 is not H;
- or
- Comprising the steps of:
- (1) Linking a compound of Formula III with a compound of Formula IV or with a compound of Formula V through creation of a phosphate diester bridge
- wherein, all substitutions are defined as above;
- and
- (2) Converting a phosphorus-bound OH group to O—R4, wherein R4 is not H.
A pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable diluent or carrier
- wherein,
- R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R3 is
- R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
- R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R8 is H or a C0-C2 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- X is a direct linkage, CH2, O or NH;
- Y is a direct linkage, CH2, O or NH;
- and,
- each stereogenic center is independently R, S or racemic.
A method of reducing or eliminating one or more of a cardiac channelopathy, cardiac muscle damage, or a condition resulting from the irregularity or alteration in the cardiac pattern, in a human or animal subject, comprising the step of administering to the human or animal subject one or more of a compound of Formula I
- wherein,
- R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R3 is
- R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
- R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
- R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- R8 is H or a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
- X is a direct linkage, CH2, O or NH;
- Y is a direct linkage, CH2, O or NH;
- and
- wherein each stereogenic center is independently R, S or racemic.
Dependencies are inferred from the claim text.